• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Business & Finance

Glaukos (GKOS) Q2 Revenue Jumps 30% todayheadline

August 1, 2025
in Business & Finance
Reading Time: 4 mins read
A A
0
6
SHARES
13
VIEWS
Share on FacebookShare on Twitter


Glaukos (GKOS -8.55%), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%. Non-GAAP earnings per share (EPS) came in at a loss of ($0.24), outperforming the anticipated ($0.26) non-GAAP loss. Both top-line and bottom-line results showed sharp improvements over the same period last year. The quarter was marked by ongoing strong adoption of its innovative glaucoma products in the U.S. and continued expansion in global markets.

Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change
EPS (Non-GAAP) ($0.24) ($0.26) ($0.52) 53.8 % (improvement)
Revenue (GAAP) $124.1 million $115.52 million $95.7 million 29.7 %
Gross Margin (Non-GAAP) 83.0 % 82.2 % 0.8 pp
SG&A Expense (Non-GAAP) $83.1 million $65.5 million 26.9 %
Net Loss (Non-GAAP) ($13.6 million) ($26.3 million) 48.3 % decrease

Source: Analyst estimates provided by FactSet. Management expectations based on management’s guidance, as provided in Q1 2025 earnings report.

About Glaukos: Business Focus and Key Drivers

Glaukos develops and commercializes innovative therapies for chronic eye diseases, including glaucoma, corneal disorders, and retinal diseases. Its leading treatments include micro-invasive glaucoma surgery (MIGS) devices, pharmaceutical implants, and therapies aimed at improving patient outcomes with less invasive approaches.

Growth for Glaukos currently depends on expanding its glaucoma franchise, launching next-generation products, and increasing reimbursement coverage. Success requires both clinical innovation and strong execution in the regulatory and market access fields. Further investment into research and development, combined with strategic expansion internationally, are cited as ongoing priorities.

Quarter Highlights: Financial and Product Progress

The quarter saw total net sales rise nearly 30 % over the prior year. Glaucoma product revenue climbed 36%, reaching $103.5 million, with U.S. glaucoma net sales jumped 45% to $72.3 million. International glaucoma sales increased 19.6%.

Gross margin edged up to 83.0% (non-GAAP), compared to 82.2% in Q2 2024. While losses remain, operating margin losses narrowed year over year. Selling, general, and administrative expenses (SG&A) rose to $83.1 million, up 27%, on a non-GAAP basis. Research and development spending grew 6% to $36.5 million, reflecting continued investment in new products and clinical trials.

Glaukos also advanced key products in its pipeline. The iDose TR implant saw rapid uptake and has been gaining broad reimbursement coverage via the U.S. J-code process, enabling easier payment across major insurers and Medicare plans. The company is launching programs to lower patients’ out-of-pocket costs, including $0 copay programs for commercial insurance holders. Its novel Epioxa therapy, a topical corneal cross-linking drug for keratoconus (a corneal disorder), is under FDA review, with a decision expected by October 2025. The company continued studies for new products like the PRESERFLO MicroShunt (an eye drainage implant for refractory glaucoma), next-generation iDose delivery systems, and investigational retinal drugs.

U.S. stent revenue, representing Glaukos’ original MIGS surgical devices, continues to face reimbursement headwinds due to local coverage determinations (LCDs), which restrict use of multiple combination devices in one procedure. This has driven a forecasted mid single-digit revenue decline for non-iDose U.S. glaucoma sales in 2025. The corneal health product line, particularly the Photrexa drug for corneal cross-linking, remains static with only flat-to-low single-digit growth expected due to ongoing changes in reimbursement for the Medicaid Drug Rebate Program (MDRP).

Glaukos ended the quarter with $278.6 million in cash, cash equivalents, short-term investments, and restricted cash, and no debt, highlighting its strong balance sheet to support ongoing investments and expansion.

Looking Ahead: Guidance and Investor Focus

Leadership raised 2025 net sales guidance (GAAP) to a range of $480 million to $486 million, reflecting increased optimism for the iDose TR growth trajectory as payer coverage expands and more physicians are trained. Operating expense guidance remains for approximately 15% year-over-year growth, consistent with continued investments into the sales force and product development. Despite these increases, the company acknowledges that profitability remains subdued with ongoing operating losses, although margins (GAAP and non-GAAP) are improving with higher sales volumes.

Investors should track updates on the commercial uptake of iDose TR, the ongoing regulatory review of Epioxa, and the company’s ability to manage spending and bring new therapies to market. Key future events include the FDA’s decision on Epioxa in October and observed progress toward operating breakeven as sales expand. GKOS does not currently pay a dividend.

Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Tags: GKOSGlaukosjumpsrevenuetodayheadline
Previous Post

Banks brace for key UK Supreme Court ruling on car finance commissions todayheadline

Next Post

China’s Yu Zidi, 12, wins relay bronze medal at swim worlds todayheadline

Related Posts

A vacancy on the Fed is opening early as Trump urges board to 'assume control' if Powell doesn't cut rates

A vacancy on the Fed is opening early as Trump urges board to ‘assume control’ if Powell doesn’t cut rates todayheadline

August 2, 2025
1
Kia America recalls 201,149 US Telluride vehicles

Kia America recalls 201,149 US Telluride vehicles todayheadline

August 2, 2025
3
Next Post

China's Yu Zidi, 12, wins relay bronze medal at swim worlds todayheadline

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
A vacancy on the Fed is opening early as Trump urges board to 'assume control' if Powell doesn't cut rates

A vacancy on the Fed is opening early as Trump urges board to ‘assume control’ if Powell doesn’t cut rates todayheadline

August 2, 2025
Kia America recalls 201,149 US Telluride vehicles

Kia America recalls 201,149 US Telluride vehicles todayheadline

August 2, 2025
ET logo

Deadly east coast storm batters New South Wales with floods, snow, and 90km/h winds todayheadline

August 2, 2025
Immigration officials can't stop people based on race, their spoken language in Los Angeles, judge rules

Appeals court keeps in place restrictions on immigration stops in L.A. based on language, job

August 2, 2025

Recent News

A vacancy on the Fed is opening early as Trump urges board to 'assume control' if Powell doesn't cut rates

A vacancy on the Fed is opening early as Trump urges board to ‘assume control’ if Powell doesn’t cut rates todayheadline

August 2, 2025
1
Kia America recalls 201,149 US Telluride vehicles

Kia America recalls 201,149 US Telluride vehicles todayheadline

August 2, 2025
3
ET logo

Deadly east coast storm batters New South Wales with floods, snow, and 90km/h winds todayheadline

August 2, 2025
5
Immigration officials can't stop people based on race, their spoken language in Los Angeles, judge rules

Appeals court keeps in place restrictions on immigration stops in L.A. based on language, job

August 2, 2025
4

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

A vacancy on the Fed is opening early as Trump urges board to 'assume control' if Powell doesn't cut rates

A vacancy on the Fed is opening early as Trump urges board to ‘assume control’ if Powell doesn’t cut rates todayheadline

August 2, 2025
Kia America recalls 201,149 US Telluride vehicles

Kia America recalls 201,149 US Telluride vehicles todayheadline

August 2, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co